Physician profile
Li Liang
NPI 1053468546
$9,351.47
in general payments reported to CMS, 2019-2025
29 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,949 · 2020: $852 · 2021: $1,290 · 2022: $1,335 · 2023: $1,475 · 2024: $1,251 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,917 · Education: $7.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,916.74 |
| Education | $7.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,137.47 | 2021-2025 | Caplyta |
| Lundbeck LLC | $1,115.52 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $970.96 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $958.36 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $743.68 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $652.59 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $582.93 | 2019-2024 | Spravato, Xarelto, Invega Sustenna |
| Allergan, INC. | $567.04 | 2019-2020 | |
| Alkermes, INC. | $416.92 | 2019-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $366.34 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $342.21 | 2019-2025 | Fanapt, Hetlioz |
| Corium, LLC | $243.14 | 2021-2024 | Azstarys |
| Axsome Therapeutics, INC. | $187.58 | 2022-2025 | Auvelity |
| Bausch Health US, LLC | $178.47 | 2019-2023 | Aplenzin |
| Shire North American Group INC | $134.61 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $113.20 | 2022-2025 | Qelbree, Qelbree |
| Corcept Therapeutics | $103.80 | 2025 | Korlym |
| Neuronetics, INC. | $98.69 | 2019-2023 | Neurostar Tms Therapy System |
| Neurocrine Biosciences, INC. | $68.40 | 2021 | |
| Ironshore Pharmaceuticals INC. | $60.68 | 2022-2023 | Jornay Pm |
| Tris Pharma INC | $60.52 | 2023 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $45.04 | 2023-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $44.14 | 2024-2025 | Cobenfy |
| Scilex Pharmaceuticals INC. | $42.43 | 2019 | |
| Alfasigma USA, INC. | $30.90 | 2021-2022 | |
| Indivior INC. | $28.73 | 2023-2024 | Sublocade, Perseris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.40 | 2024 | |
| Tms Neurohealth Centers INC. | $17.56 | 2025 | Tms Neurohealth Centers INC. |
| Jazz Pharmaceuticals INC. | $15.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li Liang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.